+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

  • ID: 5212227
  • Report
  • November 2020
  • Region: Global
  • 177 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 2cureX AB
  • Berg LLC
  • Di.V.A.L Toscana srl
  • MDNA Life Sciences Inc
  • OPKO Health Inc
  • Reccan Diagnostics AB
  • MORE
Summary

The publisher's Medical Devices sector report, “Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Pancreatic Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Pancreatic Cancer Diagnostic Tests include assays of mostly antibodies released in response to a pancreatic cancer and cancer-causing proteins.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Pancreatic Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Pancreatic Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Pancreatic Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 2cureX AB
  • Berg LLC
  • Di.V.A.L Toscana srl
  • MDNA Life Sciences Inc
  • OPKO Health Inc
  • Reccan Diagnostics AB
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Pancreatic Cancer Overview

3 Products under Development
3.1 Pancreatic Cancer - Pipeline Products by Stage of Development
3.2 Pancreatic Cancer - Pipeline Products by Territory
3.3 Pancreatic Cancer - Pipeline Products by Regulatory Path
3.4 Pancreatic Cancer - Pipeline Products by Estimated Approval Date
3.5 Pancreatic Cancer - Ongoing Clinical Trials

4 Pancreatic Cancer - Pipeline Products under Development by Companies
4.1 Pancreatic Cancer Companies - Pipeline Products by Stage of Development
4.2 Pancreatic Cancer - Pipeline Products by Stage of Development

5 Pancreatic Cancer Companies and Product Overview

6 Pancreatic Cancer- Recent Developments

7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Pancreatic Cancer - Pipeline Products by Stage of Development
Table 2: Pancreatic Cancer - Pipeline Products by Territory
Table 3: Pancreatic Cancer - Pipeline Products by Regulatory Path
Table 4: Pancreatic Cancer - Pipeline Products by Estimated Approval Date
Table 5: Pancreatic Cancer - Ongoing Clinical Trials
Table 6: Pancreatic Cancer Companies - Pipeline Products by Stage of Development
Table 7: Pancreatic Cancer - Pipeline Products by Stage of Development
Table 8: 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview
Table 9: IndiTreat - PC - Product Status
Table 10: IndiTreat - PC - Product Description
Table 11: 2cureX AB - Ongoing Clinical Trials Overview
Table 12: IndiTreat - PC - Predictive Value of In-vitro Anti-cancer Therapy Sensitivity Testing on Tumoroids from Patients with Metastatic Pancreatic Cancer
Table 13: 3rd Street Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 14: Diagnostic Test Kit - Pancreatic Ductal Adenocarcinoma - Product Status
Table 15: Diagnostic Test Kit - Pancreatic Ductal Adenocarcinoma - Product Description
Table 16: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 17: Companion Diagnostic Test - Pancreatic Cancer - Product Status
Table 18: Companion Diagnostic Test - Pancreatic Cancer - Product Description
Table 19: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Diagnostic Assay - Pancreatic Cancer - Product Status
Table 21: Diagnostic Assay - Pancreatic Cancer - Product Description
Table 22: Acobiom Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Companion Diagnostic Assay - Masitinib - Product Status
Table 24: Companion Diagnostic Assay - Masitinib - Product Description
Table 25: Diagnostic/Prognostic Assay - Pancreatic Cancer - Product Status
Table 26: Diagnostic/Prognostic Assay - Pancreatic Cancer - Product Description
Table 27: GemciTest - Product Status
Table 28: GemciTest - Product Description
Table 29: Acobiom - Ongoing Clinical Trials Overview
Table 30: GemciTest - Evaluation of GEMCITEST in Patients with Pancreatic Cancer and Treated by Chemotherapy (GEMCIPANC)
Table 31: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview
Table 32: PancreaDix - Product Status
Table 33: PancreaDix - Product Description
Table 34: Alaunus Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Diagnostic Assay - Pancreatic Cancer - Product Status
Table 36: Diagnostic Assay - Pancreatic Cancer - Product Description
Table 37: Amplified Sciences LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 38: PanCystPro - Product Status
Table 39: PanCystPro - Product Description
Table 40: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Cchek - Pancreatic Cancer Confirmatory Test - Product Status
Table 42: Cchek - Pancreatic Cancer Confirmatory Test - Product Description
Table 43: Cchek - Pancreatic Cancer Recurrence Test - Product Status
Table 44: Cchek - Pancreatic Cancer Recurrence Test - Product Description
Table 45: Cchek - Pancreatic Cancer Screening Test - Product Status
Table 46: Cchek - Pancreatic Cancer Screening Test - Product Description
Table 47: Cchek - Pancreatic Cancer Treatment Monitoring Test - Product Status
Table 48: Cchek - Pancreatic Cancer Treatment Monitoring Test - Product Description
Table 49: Anixa Diagnostics Corporation - Ongoing Clinical Trials Overview
Table 50: Cchek - Pancreatic Cancer Screening Test - The Coupling of MDSCs with a Computational Analytic Method to Detect Solid Tumors
Table 51: Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview

List of Figures
Figure 1: Pancreatic Cancer - Pipeline Products by Stage of Development
Figure 2: Pancreatic Cancer - Pipeline Products by Territory
Figure 3: Pancreatic Cancer - Pipeline Products by Regulatory Path
Figure 4: Pancreatic Cancer - Pipeline Products by Estimated Approval Date
Figure 5: Pancreatic Cancer - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 3
  • 2cureX AB
  • 3rd Street Diagnostics
  • A&G Pharmaceutical Inc
  • Abcodia Ltd
  • Acobiom
  • Advanced Marker Discovery SL
  • Alaunus Biosciences Inc
  • Amplified Sciences LLC
  • Anixa Diagnostics Corporation
  • Applied Proteomics Inc
  • Avant Diagnostics Inc
  • Axim Biotechnologies Inc
  • Berg LLC
  • BioMarker Strategies LLC
  • BiomaRx Inc
  • Bioprognos SL
  • Biouniversa srl
  • Cancer Research Technology Ltd
  • Captis Biotechnology Inc
  • Caris Life Sciences Inc
  • Cepheid Inc
  • Clovis Oncology Inc
  • Courtagen Life Sciences Inc
  • CS-Keys, Inc. (Inactive)
  • Di.V.A.L Toscana srl
  • Exact Sciences Corp
  • Fred Hutchinson Cancer Research Center
  • Fujirebio Diagnostics Inc
  • GlycoZym USA Inc
  • Health Discovery Corp
  • Houston Methodist Hospital
  • ImmunoCellular Therapeutics Ltd
  • Immunomedics Inc
  • Immunovia AB
  • Johns Hopkins University
  • JW Bioscience
  • Leitat Technological Center
  • Matrix-Bio Inc
  • MDNA Life Sciences Inc
  • Memorial Sloan Kettering Cancer Center
  • Merrimack Pharmaceuticals Inc
  • Metanomics Health GmbH
  • Milagen Inc
  • Myriad Genetics Inc
  • NanoScale Corp
  • Nanoview Biosciences Inc
  • NatiMab Therapeutics Srl
  • National Cheng-Kung University Hospital
  • Oncimmune (USA) LLC
  • Oncomatryx Biopharma SL
  • Onconome, Inc. (Inactive)
  • OPKO Health Inc
  • OTraces Inc
  • Oxford Gene Technology Ltd
  • Penn Medicine
  • Peri Rx Inc
  • Precision Biologics Inc
  • Preora Healthcare Inc
  • Proplex Technologies Llc
  • Protagen AG
  • Proteome Sciences Plc
  • Quanterix Corp
  • Reccan Diagnostics AB
  • RISE Life Science Corp
  • Rutgers The State University of New Jersey
  • Sanguine Diagnostics and Therapeutics Inc
  • SDIX LLC
  • Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • Sienna Cancer Diagnostics Ltd
  • SomaLogic Inc
  • Stanford University
  • Taizhou ZECEN Biotech Co Ltd
  • Temple University Health System
  • Thomas Jefferson University
  • University of California San Francisco
  • University of Illinois at Chicago
  • University of Liverpool
  • University of Pennsylvania
  • University of Texas MD Anderson Cancer Center
  • University of Washington
  • US Biomarkers Inc
  • Vajra Instruments Inc
  • Vastcon Inc
  • Ventana Medical Systems Inc
  • Viomics Inc.
  • VolitionRX Ltd
  • ZORA Biosciences Oy
Note: Product cover images may vary from those shown
Adroll
adroll